Compare FA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | TWST |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | 2021 | 2018 |
| Metric | FA | TWST |
|---|---|---|
| Price | $15.84 | $74.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $15.67 | ★ $46.88 |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | 63.89 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,574,389,000.00 | $376,572,000.00 |
| Revenue This Year | $8.42 | $18.91 |
| Revenue Next Year | $7.26 | $15.07 |
| P/E Ratio | $1,577.00 | ★ N/A |
| Revenue Growth | ★ 83.02 | 20.32 |
| 52 Week Low | $8.82 | $23.30 |
| 52 Week High | $19.01 | $80.50 |
| Indicator | FA | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 59.09 | 73.74 |
| Support Level | $15.63 | $41.85 |
| Resistance Level | $16.19 | N/A |
| Average True Range (ATR) | 0.69 | 4.84 |
| MACD | -0.03 | 1.71 |
| Stochastic Oscillator | 52.72 | 84.06 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.